Exploring Biohaven's Breakthroughs in Alzheimer's Research and Stock Performance

Despite a phase one trade deal with China, the Dow remained steady today, rising only 3 points, and Jim Cramer’s giving you his Game Plan to navigate next week on Wall Street. Then, Anaplan CEO Frank Calderoni sits down to talk about the stock’s recent roar, up 90% for the year, and where the company is headed from here. Then, Dr. Vlad Coric, CEO of Biohaven Pharmaceuticals is in the Mad Money studio to talk about what’s in the company’s pipeline and what it means for the company’s future. And, what should you make of the managed care company’s heading into 2020? Cramer’s talking with Centene’s CEO, Michael Neidorff, to discuss the stock’s recent decline how you should interpret the company’s new guidance and its acquisition of WellCare.